Anakinra treatment in multisystemic inflammatory syndrome in ...

Based on the results of the study, anakinra was associated with clinical improvements and was safe for most patients with refractory MIS-C.

Anakinra treatment in multisystemic inflammatory syndrome ... - NCBI

Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. (2020) 2:393–400. 10.1016/S2665-9913(20)30164-8

Clinical outcomes and safety of anakinra in the treatment of ...

Evidence for the treatment of multisystem inflammatory syndrome in children (MIS-C) is lacking. Anakinra, which targets IL-1-mediated ...

Early anakinra treatment improves cardiac outcome of multisystem ...

The main aim of this study was to define the best treatment option for multisystem inflammatory syndrome in children (MIS-C) and to analyse the ...

Outcomes of MIS-C patients treated with anakinra - Frontiers

Background: The treatment of multisystem inflammatory syndrome in children unresponsive to first-line therapies (IVIG and/or steroids) is challenging. The ...

Impact of anakinra use on clinical outcomes in children with ...

The treatment of children with multisystem inflammatory syndrome in children (MIS-C) related to SARS-CoV-2 infection involves ...

Early anakinra treatment improves cardiac outcome of multisystem ...

Early anakinra treatment improves cardiac outcome of multisystem inflammatory syndrome in children, regardless of disease severity.

Abstract 15506: Pattern of Use of Anakinra for Patients With ...

For KD, anakinra was used for treatment resistance for 5 sites, evolving aneurysms 3, macrophage activation syndrome (MAS) 1 and not-specified ...

Subcutaneous anakinra in the management of refractory MIS-C in ...

Multisystemic inflammatory syndrome in children (MIS-C) is a therapeutic emergency and can lead to myocardial dysfunction (17%–75%) (1, 2) and heart failure in ...

(PDF) Anakinra treatment in multisystemic inflammatory syndrome in ...

Methods This is a cross-sectional retrospective study consisting of pediatric patients diagnosed with MIS-C who were treated with anakinra.

A rare sequela of SARS-CoV-2 infection - ScienceDirect

In its recommendations regarding MIS-A, the American College of Rheumatology has mentioned that anakinra can be considered as an additional therapy in patients ...

Multisystem Inflammatory Syndrome in an Adult (MIS-A ... - MDPI

To our knowledge, this is the first report of the successful use of anakinra for MIS-A, a drug that has already proven useful in the treatment of refractive ...

Treatment of MIS-C in Children and Adolescents

Anakinra is a recombinant human IL-1 receptor antagonist (IL-1ra) used for rheumatoid arthritis and other inflammatory conditions, including ...

The Trilogy of SARS-CoV-2 in Pediatrics (Part 2) - Allen Press

Anakinra is FDA approved for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease. Anakinra is frequently ...

Anakinra Linked to Longer Hospital Stay in Multisystem ...

Researchers assessed the impact of anakinra on reducing hospital stays among patients with moderate to severe multisystem inflammatory ...

Clinical Treatment of Multisystem Inflammatory Syndrome in Children

... therapy.1. Prolonged duration of outpatient steroids should be avoided.2 The use of other anti-inflammatory medications (e.g., anakinra) and ...

Anakinra treatment in multisystemic inflammatory syndrome ... - OUCI

ObjectiveThe study aimed to report the efficacy and safety of anakinra treatment in patients with the refractory multisystemic inflammatory syndrome in ...

Outcomes and Safety of Anakinra for the Treatment of Multisystem ...

Results: Of the 46 MIS-C patients included in the study, all received IVIG, 14 (30%) received IVIG monotherapy and 32 (70%) received IVIG+anakinra. No mortality ...

Use of Continuous Intravenous Anakinra Infusion in Multisystem ...

One of its complications in children is developing multisystemic inflammatory syndrome related to cytokine storm. Anakinra is a recombinant ...

Anakinra in Refractory Multisystem Inflammatory Syndrome in ...

... More recently, case reports and case series of patients with MIS-C reported the efficacy of treatment with anakinra, highlighting its role particularly in ...